Precision oncology depends on access to biomarker‑defined samples, but most clinical biospecimens lack molecular data, slowing research and increasing costs. This video shows how pre‑sequenced biospecimens, powered by Discovery’s SpecimenSeq platform, streamline biomarker‑driven oncology studies.
By eliminating the need for separate sequencing workflows, SpecimenSeq biospecimens reduce turnaround time, operational complexity, and cost, accelerating precision oncology research. Explore the full list of genes and variants available on our website at www.dls.com.